Condition: Prostate Cancer, Prostatic Neoplasms

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT06925737

Sponsor: Merck Sharp & Dohme LLC

Phase: Phase 3

Eligibility:

• Age: minimum 18 Years maximum N/A
• Gender: Male

Inclusion Criteria:

• The main inclusion criteria include but are not limited to the following:
• Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
• Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study
• Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment Exclusion Criteria: The main

Exclusion Criteria:

• The main exclusion criteria include but are not limited to the following:
• History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids
• Has uncontrolled or significant cardiovascular disease
• Has received prior treatment with a taxane-based chemotherapy agent for mCRPC

View trial on ClinicalTrials.gov